Geneva Capital Management LLC Sells 4,997 Shares of STERIS plc $STE

Geneva Capital Management LLC reduced its position in shares of STERIS plc (NYSE:STE) by 4.7% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 102,344 shares of the medical equipment provider’s stock after selling 4,997 shares during the period. Geneva Capital Management LLC owned about 0.10% of STERIS worth $25,324,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Steigerwald Gordon & Koch Inc. bought a new position in shares of STERIS in the 3rd quarter valued at about $25,000. Cloud Capital Management LLC acquired a new position in shares of STERIS during the third quarter worth about $29,000. Geneos Wealth Management Inc. grew its holdings in shares of STERIS by 416.0% during the first quarter. Geneos Wealth Management Inc. now owns 129 shares of the medical equipment provider’s stock worth $29,000 after buying an additional 104 shares in the last quarter. TruNorth Capital Management LLC acquired a new stake in STERIS in the 3rd quarter valued at approximately $37,000. Finally, Root Financial Partners LLC acquired a new stake in STERIS in the 3rd quarter valued at approximately $39,000. 94.69% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. Weiss Ratings reaffirmed a “buy (b)” rating on shares of STERIS in a research report on Friday, January 9th. Wall Street Zen upgraded shares of STERIS from a “buy” rating to a “strong-buy” rating in a research note on Saturday, March 7th. Six analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, STERIS presently has an average rating of “Moderate Buy” and an average price target of $275.20.

STERIS Stock Down 0.2%

Shares of STE opened at $221.66 on Thursday. The company has a current ratio of 2.48, a quick ratio of 1.75 and a debt-to-equity ratio of 0.26. STERIS plc has a 12 month low of $204.90 and a 12 month high of $269.44. The firm’s 50 day moving average is $252.49 and its 200-day moving average is $251.00. The stock has a market capitalization of $21.74 billion, a PE ratio of 30.91 and a beta of 1.05.

STERIS (NYSE:STE) last announced its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $2.53 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $2.53. STERIS had a net margin of 12.15% and a return on equity of 14.34%. During the same quarter in the prior year, the business earned $2.32 EPS. STERIS’s quarterly revenue was up 9.2% on a year-over-year basis. STERIS has set its FY 2026 guidance at 10.150-10.300 EPS. Equities research analysts forecast that STERIS plc will post 9.08 EPS for the current year.

STERIS Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 19th. Investors of record on Tuesday, February 17th will be paid a $0.63 dividend. The ex-dividend date of this dividend is Tuesday, February 17th. This represents a $2.52 annualized dividend and a yield of 1.1%. STERIS’s dividend payout ratio (DPR) is 35.15%.

Insiders Place Their Bets

In other news, Director Cynthia L. Feldmann sold 3,098 shares of the firm’s stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $237.21, for a total value of $734,876.58. Following the sale, the director directly owned 705 shares in the company, valued at approximately $167,233.05. This trade represents a 81.46% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 1.07% of the stock is owned by company insiders.

STERIS Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.